Cervical keratinizing squamous cell carcinoma

Summary

Cervical keratinizing squamous cell carcinoma (MONDO:0004239) is a cancer. A subtype of keratinizing squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cervical keratinizing squamous cell carcinoma
Mondo ID	MONDO:0004239
DOID	DOID:7483
NCIT	C40187
UMLS	C1517658
MedGen	309255
GARD	0023894
Anatomy (UBERON)	UBERON:0000002
Is cancer (heuristic)	yes

Also known as: cervical keratinizing squamous cell carcinoma

Data availability: 4 cell lines.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › keratinizing squamous cell carcinoma › cervical keratinizing squamous cell carcinoma

Related subtypes (7): sarcomatoid squamous cell skin carcinoma, skin basaloid carcinoma, vulvar keratinizing squamous cell carcinoma, large cell keratinizing variant squamous cell breast carcinoma, acantholytic squamous cell skin carcinoma, pseudovascular skin squamous cell carcinoma, clear cell squamous cell skin carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.